/Investor DB

TEDCO — 2021 Investments

6 investments dated 2021 · listed companies and verified rows first · show all

Audiooneaudioone.fyiApr 2021

Bethesda, US

Antonio Bray(Director)

Co-investorsMaryland TEDCO

Haystack Solutionshaystacksolutions.comin𝕏Nov 2021

Haystack Solutions offers CyberGEN.IQ, a cyber aptitude and talent assessment that uses cognitive tests to measure a person's strengths across cognitive dimensions relevant to cybersecurity work.

CybersecurityEdTechHR TechCollege Park, US

Doug Britton(Executive Officer, Director, Promoter)

Co-investorsMaryland TEDCO

Minnowtechminnowtech.comin𝕏Mar 2021

Minnowtech develops precision aquaculture technology using integrated sensor-based systems to help aquafarmers assess and maximize their cultivation efforts.

AgTechFoodTechHardwareIoTBaltimore, US

Suzan Shahrestani(Founder)inKelli Booth(Co-Founder & CEO)inKen Malone(Co-Founder)inQuynh Vo(Chief Technology Officer)in

Co-investorsMaryland TEDCOTCP Venture CapitalUniversity System of Maryland Momentum FundBlue Revolution Investments G.P.

Seraxisseraxis.comin𝕏Jan 2021

Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients.

BiotechHealthtechGermantown, US

William L. Rust(Executive Officer, Director, Promoter)inCarole Welsch(Executive Officer)inGi-Hyeok Yang(Director)Roy Arup(Director)Bernie Treidl(Director)

BoardJames N. Topper(Director)

Co-investorsFrazier Life SciencesMaryland TEDCOJDRF T1D Fund

Truveloptruvelop.cominMar 2021

Truvelop is a performance management platform that lets managers deliver continuous, data-driven feedback, coaching, and employee evaluations, and provides leadership development resources for front-line managers.

Future of WorkHR TechSaaS

Lisa First-Willis(Founder)in

Co-investorsMaryland TEDCOEvergreen Mountain Equity Partners

Veraloxveralox.comJun 2021acquired by Cadrenal Therapeutics · Dec 2025 · $200K

Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.

Co-investorsAlumni VenturesHatteras Venture PartnersPappas CapitalSanofi VenturesAlexandriaGenesys Capital+4 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.